findmyKOL

Harry Menon, DO, MPH

Basic profile

Renown Regional Medical Center

ORCIDNone on fileNPI
RegionReno, NV · WestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Harry Menon is an Oncology physician affiliated with Renown Regional Medical Center. OpenAlex indexes 17 publications with 2,243 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
17publications

Distinct works indexed by OpenAlex.

2,243citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
43companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1155 Mill St
Reno, NV 895021576

Telephone

775-982-5436

Provider last certified this registry record 13 Jul 2023.

View the NPPES registry record

Industry payments

43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    27.8%
    Serotonin-3 Receptor Antagonist13.3%
    Ondansetron Hcl91%Ondansetron Odt9%
    Part D<11 patients
    Corticosteroid7.9%
    Prednisone100%
    Part D32 patients

    + 4 more classes in this area

  • Nervous system

    20.5%
    Phenothiazine9.9%
    Prochlorperazine Maleate100%
    Part D84 patients
    Opioid Agonist3.9%
    Oxycodone Hcl60%Oxycodone-Acetaminophen40%
    Part D16 patients

    + 4 more classes in this area

  • Cancer & immunology

    18.7%
    Thalidomide Analog7.7%
    Revlimid67%Pomalyst20%Lenalidomide13%
    Part D<11 patients
    Kinase inhibitor4.7%
    Brukinsa30%Jakafi30%Lenvima21%Cabometyx19%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)96.1% facility · 3.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”